A new exosome carrier could make oral CBD work more reliably

A microfluidic and mechanistic modeling approach to enhance oral bioavailability of cannabidiol via poloxamer-coated camel milk exosomes.

International journal of pharmaceutics • • Highly Relevant
🤖

AI Summary

Cannabidiol (CBD) is difficult to deliver by mouth because it dissolves poorly in water, can be absorbed inconsistently, and is extensively processed by the liver before reaching the bloodstream. This study tested camel milk-derived exosomes coated with Poloxamer 407 as a nanoscale carrier designed to protect CBD in the stomach and release it gradually in the intestine. The coated particles remained stable, reduced early release under simulated gastric conditions, and supported controlled intestinal release. In laboratory cell models, the formulation also showed higher epithelial permeability than the control, with a reported Papp of 29.56 × 10⁻⁶ cm/s.

In rats, the coated exosome formulation increased systemic CBD exposure after oral dosing, reaching a Cmax of 719.58 ng/mL and an AUC₀–₂₄h of 2947.88 h·ng/mL. A custom microfluidic dissolution chip reproduced the same formulation ranking as conventional testing, while GastroPlus physiologically based pharmacokinetic modeling supported improved absorption, especially in the proximal small intestine. These results are proof-of-concept evidence, not evidence of improved effects or safety in people; the authors note that long-term stability, safety, reproducibility, and pharmacodynamic relevance still require further study.

💡 Key Findings

1
Poloxamer 407-coated camel milk exosomes protected CBD from premature gastric release and enabled controlled intestinal release in laboratory testing.
Good
60%
2
The coated exosome formulation showed higher epithelial permeability than the control in an MDCK cell model, with a Papp of 29.56 × 10⁻⁶ cm/s.
Moderate
55%
3
In rats, oral CBD delivered with the coated exosomes produced increased systemic exposure, including a Cmax of 719.58 ng/mL and an AUC₀–₂₄h of 2947.88 h·ng/mL.
Moderate
55%
4
A microfluidic dissolution chip reproduced the conventional test’s formulation ranking, suggesting it could be a useful low-volume tool for evaluating nanocarrier release.
Moderate
50%
5
The study provides proof-of-concept evidence for improved oral CBD delivery, but human effectiveness, long-term safety, stability, and pharmacodynamic benefits remain unestablished.
Good
60%

📄 Original Abstract

Cannabidiol (CBD) has significant therapeutic potential, but its oral delivery remains limited by poor aqueous solubility, variable intestinal absorption, and extensive first-pass metabolism. This study evaluated Poloxamer 407-coated camel milk-derived exosomes (CBD-CMDE-P407) as an oral nanocarrier system for improving CBD delivery. The relationship between in vitro release, epithelial permeability, in vivo pharmacokinetics, and GastroPlus® PBPK-based absorption prediction was also examined. CBD-loaded CMDE were successfully prepared with a particle size of 126.11 ± 0.75 nm, while P407 coating increased the hydrodynamic diameter to 142.3 ± 2.1 nm without evidence of major vesicle destabilization. CBD-CMDE-P407 reduced premature CBD release under simulated gastric conditions and supported sustained CBD release under intestinal pH, indicating improved gastric protection and controlled intestinal drug availability. In MDCK monolayers, CBD-CMDE-P407 showed higher apparent permeability than the control formulation, with a Papp of 29.56 × 10-6 ± 0.78 cm/s. Following oral administration in rats, CBD-CMDE-P407 increased systemic CBD exposure compared with the control formulation, with Cmax of 719.58 ± 27.63 ng/mL and AUC0-24 h of 2947.88 ± 124.03 h·ng/mL. A custom microfluidic dissolution chip reproduced the formulation rank order observed with conventional USP dissolution testing and may serve as a complementary low-volume platform for evaluating nanocarrier release behavior. GastroPlus® PBPK modeling further supported the experimental trends, predicting improved absorption for exosome-based formulations, mainly in the proximal small intestine. Overall, these findings provide proof-of-concept evidence that P407-coated CMDE may improve oral CBD delivery through gastric protection, controlled intestinal release, and enhanced epithelial transport. Further studies are needed to establish long-term stability, safety, reproducibility, and pharmacodynamic relevance.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.